Improving quality control for CAR T cell therapies
Drug Discovery World
AUGUST 10, 2022
By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. In 1987, researchers developed the chimeric antigen receptor (CAR) as an alternative means to identify cancer cells and direct T cells to attack them.
246 
Let's personalize your content